Corvus Pharmaceuticals CRVS
NASDAQ CRVS
$14.43 -0.22 (-1.49%)
As of: Sep 4, 2026 · 3:19 PM EDT

Corvus Pharmaceuticals (CRVS) Net Equity Issued and Repurchased (2015 - 2026)

Corvus Pharmaceuticals (CRVS) posted quarterly Net Equity Issued and Repurchased of $189.4 million for Q1 2026, up 492.1% quarter-over-quarter from $32.0 million in Q1 2021.

Analysis

Corvus Pharmaceuticals (CRVS) Net Equity Issued and Repurchased (2015 - 2026) Analysis & Trends

Corvus Pharmaceuticals' Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at $189.4 million for Q1 2026.

  • In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $189.4 million; the TTM figure through Mar 2026 stood at $189.4 million (changed N/A YoY), while the FY2025 annual figure was $100.0 million, up 509.57% from the prior year.
  • Net Equity Issued and Repurchased for Q1 2026 stood at $189.4 million, up from $32.0 million in the prior quarter.
  • The five-year high for Net Equity Issued and Repurchased was $189.4 million in Q1 2026, with the low at $189.4 million in Q1 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn -
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn -
5 Revolution Medicines 43.98 Bn 43.98 Bn - 141.90 Mn
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn -
8 Royalty Pharma 28.42 Bn 27.58 Bn - -
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn -
10 Corvus Pharmaceuticals 1.33 Bn 1.12 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 189.41 Mn
Mar 31, 2021 31.99 Mn
Dec 31, 2020 1.20 Mn
Jun 30, 2018 -23,000.00
Mar 31, 2018 64.90 Mn
Dec 31, 2016 -1,000.00
Jun 30, 2016 7.01 Mn
Mar 31, 2016 64.34 Mn
Sep 30, 2015 74.84 Mn
Jun 30, 2015 16.70 Mn
Mar 31, 2015 4.00 Mn